Prothena Corporation plc
https://www.prothena.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Prothena Corporation plc
BMS Revs R&D Engine To Advance 10 New Drug Candidates Annually
Bristol aims to bring more drugs into the clinic as fast as possible without compromising on quality, with many novel molecules emerging from its productive protein degradation and cell therapy platforms.
Does Prothena Have A Best-In-Class Alzheimer’s Drug Waiting In The Wings?
More than 20 years since its forerunner tried to develop the first anti-amyloid drug, Prothena’s CEO tells Scrip about its hopes for producing a best-in-class subcutaneous treatment for Alzheimer’s disease.
TauRx To File First Tau-Targeting Drug For Alzheimer’s Following Additional Pivotal Data
After previous late-stage setbacks, the Singaporean firm TauRx’s tau aggregation inhibitor asset has succeeded in a pivotal Alzheimer’s disease trial with promising new biomarker data sparking plans for regulatory filings in the US and UK.
BMS And Prothena’s Expanded Deal Shows Growing Confidence In Targeting Tau
After serial failures with tau antibodies for Alzheimer’s, BMS’ expanded deal with Prothena signals its growing confidence in PRX005, a new molecule targeting a different region on the toxic protein.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Neotope Biosciences Limited
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice